Sanofi-backed Nuvig marches lead autoimmune therapy into phase 2 with $161M series B dincorvaia Wed, 12/04/2024 - 17:32.: Big Pharma-backed immunomodulation biotech Nuvig Therapeutics is moving its lead asset into phase 2 trials using a $161 million war chest. The series B fundraising round was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities and Norwest Venture Partners, the company announced in a Dec. 5 release. Novo Holdings and Bristol Myers Squibb, original backers of Nuvig’s $47 million debut in 2022, also participated.